Advanced search
Publication Cover
Autoimmunity Volume 38, 2005 - Issue 1
Submit an article Journal homepage
844
Views
96
CrossRef citations to date
0
Altmetric
Original Article

Anti-Mi-2 antibodies

Anna Ghirardello Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
,
Sandra Zampieri Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
,
Luca Iaccarino Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
,
Elena Tarricone Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
,
Raffaele Bendo* Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
,
Pier Franca Gambari Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
&
Andrea Doria Division of Rheumatology, Medical Clinics*, Department of Medical and Surgical Sciences, University of Padova, Padova, ItalyCorrespondence[email protected]
 show all
Pages 79-83 | Received 08 Jul 2004, Accepted 08 Aug 2004, Published online: 07 Jul 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Autoantibodies targeting the Mi-2 nuclear antigen represent one of the serologic hallmarks of idiopathic inflammatory myopathies, with a diagnostic sensitivity and specificity of approximately 4–18% and 98–100%, respectively. Mi-2 antigen is a component of the nuclesome remodeling-deacetylase (NuRD) complex involved in transcription regulation.

Anti-Mi-2 antibodies are strongly associated with dermatomyositis (frequency up to 31%) and have a very high positive predictive value for such disease subset. A strong correlation with HLA-DR7 has been demonstrated.

At the moment, optimal serologic testing is achieved by ELISA screening on ricombinant Mi-2 antigen and confirmation of positive results on immunoblot.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.